Feasibility of tumor testing for BRCA status in high grade serous ovarian cancer using fresh-frozen tissue based approach
The presence of a BRCA mutation has been an important predictor of increased risk of breast and ovarian cancer. Now, with the development of targeted therapy via PARP inhibitors, it is important to know the BRCA status for all women with ovarian cancer.
This study looks at 456 women with stage III/IV ovarian cancer and the efficacy of frozen section diagnosis, at the time of initial surgery, to determine the presence of BRCA variants, which may respond to targeted therapy.
The results show 32% of the women had BRCA variants and that the frozen section analysis was accurate for 86% of cases. This means that it is possible to commence appropriate therapy more quickly and for more patients.
No comments:
Post a Comment